DE60332842D1 - Antagonisten des nogo-rezeptors - Google Patents

Antagonisten des nogo-rezeptors

Info

Publication number
DE60332842D1
DE60332842D1 DE60332842T DE60332842T DE60332842D1 DE 60332842 D1 DE60332842 D1 DE 60332842D1 DE 60332842 T DE60332842 T DE 60332842T DE 60332842 T DE60332842 T DE 60332842T DE 60332842 D1 DE60332842 D1 DE 60332842D1
Authority
DE
Germany
Prior art keywords
nogo receptor
nogo
antagonists
antigen
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60332842T
Other languages
English (en)
Inventor
Daniel H Lee
Blake R Pepinsky
Weiwei Li
Sylvia A Rabacchi
Jane K Relton
Dane S Worley
Stephen M Strittmatter
Dinah Y Sah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Biogen Inc
Biogen MA Inc
Original Assignee
Yale University
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University, Biogen Idec Inc, Biogen Idec MA Inc filed Critical Yale University
Application granted granted Critical
Publication of DE60332842D1 publication Critical patent/DE60332842D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma
DE60332842T 2002-08-10 2003-08-07 Antagonisten des nogo-rezeptors Expired - Lifetime DE60332842D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40286602P 2002-08-10 2002-08-10
PCT/US2003/025004 WO2004014311A2 (en) 2002-08-10 2003-08-07 Nogo receptor antagonists

Publications (1)

Publication Number Publication Date
DE60332842D1 true DE60332842D1 (de) 2010-07-15

Family

ID=31715907

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60332842T Expired - Lifetime DE60332842D1 (de) 2002-08-10 2003-08-07 Antagonisten des nogo-rezeptors

Country Status (21)

Country Link
US (2) US7465705B2 (de)
JP (3) JP2005535329A (de)
KR (1) KR20050062525A (de)
CN (1) CN1681838A (de)
AT (1) ATE469913T1 (de)
AU (1) AU2003264033A1 (de)
BR (1) BR0313331A (de)
CA (1) CA2495121A1 (de)
DE (1) DE60332842D1 (de)
DK (1) DK1534736T3 (de)
EA (1) EA200500330A1 (de)
ES (1) ES2346868T3 (de)
IL (2) IL166659A0 (de)
IS (1) IS7677A (de)
MX (1) MXPA05001615A (de)
NO (1) NO20050685L (de)
PL (1) PL375301A1 (de)
PT (1) PT1534736E (de)
RS (2) RS20050129A (de)
WO (1) WO2004014311A2 (de)
ZA (2) ZA200501135B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
US20030124704A1 (en) * 2000-10-06 2003-07-03 Strittmatter Stephen M. Nogo receptor homologs
EP2301564A1 (de) 2002-05-04 2011-03-30 Acorda Therapeutics, Inc. Zusammensetzungen und verfahren zur förderung des neuronalen wachstums
PL375301A1 (en) 2002-08-10 2005-11-28 Biogen Idec Ma Inc. Nogo receptor antagonists
ES2366333T3 (es) * 2002-08-15 2011-10-19 Acorda Therapeutics, Inc. Proteína quimérica.
HUE025347T2 (en) 2003-03-19 2016-02-29 Biogen Ma Inc NOGO receptor binding protein
BRPI0409562A (pt) * 2003-04-16 2006-04-18 Univ Yale tratamento de condições envolvendo placas amilóides
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
EP3514238B1 (de) * 2003-05-16 2021-05-05 Acorda Therapeutics, Inc. Proteoglycan-abbauende mutanten zur behandlung des zns
ES2420510T3 (es) * 2003-05-16 2013-08-23 Acorda Therapeutics, Inc. Composiciones y métodos para el tratamiento de lesiones del SNC
US20080274112A1 (en) * 2003-08-07 2008-11-06 Lee Daniel H S Nogo Receptor Antagonists
US8912144B2 (en) 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine
BRPI0507272A (pt) * 2004-01-30 2007-06-26 Biogen Idec Inc tratamento de condições que envolvem degeneração neuronal dopaminérgica, usando antagonistas do receptor nogo
JP4926962B2 (ja) 2004-05-18 2012-05-09 アコーダ セラピューティクス、インク． コンドロイチン分解酵素とその安定な製剤の精製法
AU2005258335B2 (en) 2004-06-24 2011-03-17 Biogen Ma Inc. Treatment of conditions involving demyelination
CN101014245A (zh) 2004-08-03 2007-08-08 比奥根艾迪克Ma公司 神经元功能中的taj
US20090111753A1 (en) * 2004-10-01 2009-04-30 Yale University Nogo-A Polypeptide Fragments, Variant Nogo Receptor-1 Polypeptides, and Uses Thereof
US7893032B2 (en) 2005-07-07 2011-02-22 Yale University NgR variants and compositions thereof for suppressing axonal growth inhibition
AU2006269458B2 (en) 2005-07-08 2012-11-08 Biogen Ma Inc. Sp35 antibodies and uses thereof
WO2007025219A2 (en) * 2005-08-25 2007-03-01 Biogen Idec Ma Inc. Nogo receptor polypeptides and polypeptide fragments and uses thereof
EP1928490B8 (de) 2005-09-26 2012-10-03 Acorda Therapeutics, Inc. Zusammensetzungen und verfahren zur verwendung von chondroitinase-abci-mutanten
EP1967582A4 (de) * 2005-12-26 2009-04-15 Kuraray Co Material für die zellkultur
CN103215293B (zh) 2006-01-27 2015-10-28 比奥根Ma公司 Nogo受体拮抗剂
JP2009538282A (ja) * 2006-05-15 2009-11-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 乏突起膠細胞の生存を促進させるためのＮｏｇｏ受容体−１（ＮｇＲ１）アンタゴニストの使用
US8642040B2 (en) 2006-07-24 2014-02-04 Biogen Idec Ma Inc. Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of Sp35 or TrkA antagonists
EP2081429A4 (de) * 2006-08-31 2010-01-06 Biogen Idec Inc Verfahren zur peripheren verabreichung von nogo-rezeptor-polypeptiden
CA2663857C (en) 2006-09-20 2017-10-31 The Board Of Regents Of The University Of Texas System Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
EP2450442B1 (de) 2006-10-10 2017-07-19 Acorda Therapeutics, Inc. Zusammensetzungen und verfahren zur verwendung von chondroitinase-abci-mutanten
JP5653622B2 (ja) 2006-11-21 2015-01-14 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ Ｎｏｇｏ−６６受容体（ＮＧＲ）に対する中和モノクローナル抗体及びその使用
WO2009070957A1 (fr) * 2007-12-05 2009-06-11 Institute Of Genetics And Developmental Biology Chinese Academy Of Sciences Inhibiteur de l'interaction entre blys et ngr et son utilisation
CA2712731C (en) 2008-01-22 2016-05-03 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
EP2276500A4 (de) * 2008-03-13 2015-03-04 Univ Yale Reaktivierung des axonenwachstums und der axonenerholung bei chronischen rückenmarksverletzungen
CA2729961C (en) 2008-07-09 2018-05-01 Biogen Idec Ma Inc. Li113, li62 variant co2, anti-lingo antibodies
US20110268729A1 (en) * 2008-07-11 2011-11-03 Bams Abila Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist
US20110020359A1 (en) * 2009-07-24 2011-01-27 California Institute Of Technology Methods and compositions for treating neuronal damage or degeneration
WO2013155103A1 (en) 2012-04-09 2013-10-17 Case Western Reserve University Compositions and methods for inhibiting the activity of lar family phosphatases
EA030716B1 (ru) 2012-05-14 2018-09-28 Байоджен Ма Инк. Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
KR101685109B1 (ko) * 2014-12-22 2016-12-09 경북대학교 산학협력단 근육 분화, 재생, 또는 질환 상태와 관련된 노고-에이의 용도
EP3242893A1 (de) 2015-01-08 2017-11-15 Biogen MA Inc. Lingo-1-antagonisten und verwendungen zur behandlung von demyelinisierungserkrankungen
CN113527462B (zh) * 2020-04-22 2023-05-23 北京大学 一种具有镇痛作用的小分子肽及其特异性抗体

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
WO1986005807A1 (en) 1985-04-01 1986-10-09 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE185601T1 (de) 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
EP0575485A1 (de) 1991-03-01 1993-12-29 Dyax Corp. Verfahren zur entwicklung bindender miniproteine
IE921169A1 (en) 1991-04-10 1992-10-21 Scripps Research Inst Heterodimeric receptor libraries using phagemids
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
WO2000073452A2 (en) 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
AU4682999A (en) 1998-06-16 2000-01-05 Human Genome Sciences, Inc. 94 human secreted proteins
AU771751C (en) 1998-12-01 2006-04-06 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US7041474B2 (en) 1998-12-30 2006-05-09 Millennium Pharmaceuticals, Inc. Nucleic acid encoding human tango 509
US20020012965A1 (en) 2000-01-12 2002-01-31 Strittmatter Stephen M. Nogo receptor-mediated blockade of axonal growth
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20030124704A1 (en) 2000-10-06 2003-07-03 Strittmatter Stephen M. Nogo receptor homologs
WO2003018631A2 (en) 2001-08-27 2003-03-06 Novartis Ag Nogo receptor homologues and their use
US20050221420A1 (en) 2001-10-22 2005-10-06 Carmen Barske Nogo receptor homologues and their use
US20030113325A1 (en) 2001-12-03 2003-06-19 Zhigang He Reducing myelin-mediated inhibition of axon regeneration
US7309485B2 (en) 2001-12-03 2007-12-18 Children's Medical Center Corporation Reducing myelin-mediated inhibition of axon regeneration
EP1354892A1 (de) 2002-04-19 2003-10-22 Centre National De La Recherche Scientifique (Cnrs) Peptide zur Induktion von axonalem Wachstum und ihre Verwendung für die Behandlung neurodegenerativer Erkrankungen
US7745151B2 (en) 2002-08-02 2010-06-29 Children's Medical Center Corporation Methods of determining binding between Nogo receptor and p75 neurotrophin receptor
PL375301A1 (en) 2002-08-10 2005-11-28 Biogen Idec Ma Inc. Nogo receptor antagonists
BRPI0409562A (pt) 2003-04-16 2006-04-18 Univ Yale tratamento de condições envolvendo placas amilóides
US20080274112A1 (en) 2003-08-07 2008-11-06 Lee Daniel H S Nogo Receptor Antagonists
CA2535007A1 (en) 2003-08-07 2005-02-24 Biogen Idec Ma Inc. Nogo receptor antagonists
BRPI0507272A (pt) * 2004-01-30 2007-06-26 Biogen Idec Inc tratamento de condições que envolvem degeneração neuronal dopaminérgica, usando antagonistas do receptor nogo
EP2081429A4 (de) 2006-08-31 2010-01-06 Biogen Idec Inc Verfahren zur peripheren verabreichung von nogo-rezeptor-polypeptiden

Also Published As

Publication number Publication date
DK1534736T3 (da) 2010-09-20
IL173559A0 (en) 2006-07-05
KR20050062525A (ko) 2005-06-23
CA2495121A1 (en) 2004-02-19
CN1681838A (zh) 2005-10-12
IS7677A (is) 2005-01-28
WO2004014311A3 (en) 2004-04-29
US7465705B2 (en) 2008-12-16
US8030456B2 (en) 2011-10-04
US20050271655A1 (en) 2005-12-08
US20090215691A1 (en) 2009-08-27
IL166659A0 (en) 2006-01-15
WO2004014311A2 (en) 2004-02-19
JP2010207239A (ja) 2010-09-24
AU2003264033A1 (en) 2004-02-25
MXPA05001615A (es) 2005-08-19
PT1534736E (pt) 2010-09-07
RS20060089A (en) 2008-08-07
ZA200501135B (en) 2006-10-25
EA200500330A1 (ru) 2006-06-30
RS20050129A (en) 2007-06-04
ATE469913T1 (de) 2010-06-15
PL375301A1 (en) 2005-11-28
ES2346868T3 (es) 2010-10-21
JP2011173899A (ja) 2011-09-08
ZA200601909B (en) 2007-05-30
JP2005535329A (ja) 2005-11-24
BR0313331A (pt) 2007-07-24
NO20050685L (no) 2005-05-10

Similar Documents

Publication Publication Date Title
DE60332842D1 (de) Antagonisten des nogo-rezeptors
IS8339A (is) Mótlyf viðtaka NOGO
WO2007089601A3 (en) Nogo receptor antagonists
CY1111097T1 (el) Πρωτεϊνη δεσμευσης του υποδοχεα nogo
WO2002068646A3 (en) Mammalian cytokines; receptors; related reagents and methods
EP1433792A3 (de) Menschlische-rezeptor Proteine; verwandte Reagenzien und Methoden
EA200600376A1 (ru) Антагонисты nogo-рецептора